Cervical Cancer Diagnostic Tests Market (Diagnostic Test: Pap Smear Test, HPV Test, Colposcopy, Biopsy & Endocervical Curettage, and Other Diagnostic Tests)- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

According to Nova one advisor, the global Cervical Cancer Diagnostic Tests market was valued at USD 8.18 billion in 2021 and it is expected to hit around USD 14.6 billion by 2030 with a CAGR of 4.60% during the forecast period 2022 to 2030.

Cervical cancer is a medical condition in which cells present in the lining of the cervix gradually develop into pre-cancerous mass of cells that ultimately turn into cancerous tumors. Two key types of cervical cancers that are typically screened and diagnosed in women are adenocarcinoma and squamous cell carcinoma. According to the World Health Organization (WHO), cervical cancer is the second most commonly prevalent cancer and the third-largest cause of death in women, with 530,000 new cases discovered each year.

Human papillomavirus (HPV) infection is responsible for 99% of the cervical cancer cases. Increase in incidence of weakened immune system, rapid spread of human papillomavirus (HPV) infection among the female population, and long-term use of oral contraceptive pills are the primary factors boosting the growth of the global cervical cancer diagnostic tests market. Moreover, other lifestyle-related factors such as smoking, multiple sex partners, and certain family history of cervical cancer are anticipated to fuel the growth of the global cervical cancer diagnostic tests market in the near future.

However, lack of education regarding the prevalence of cervical cancer and reluctance of the female population to undergo cervical cancer prognosis are projected to hamper the growth of the global cervical cancer diagnostic tests market. Moreover, unfavorable taxation and dearth of favorable reimbursement policies in countries of Europe and Asia Pacific are anticipated to restrain the global cervical cancer diagnostic tests market.

Report Scope of the Cervical Cancer Diagnostic Tests Market

Rise in Prevalence of Cervical Cancer to Drive Global Cervical Cancer Diagnostics Market

The increase in prevalence of cervical cancer among women propels the global cervical cancer diagnostics market. In 2018, an estimated 570,000 women were diagnosed with cervical cancer globally and about 311,000 women succumbed to the disease. According to the World Health Organization (WHO), over 270,000 women die every year due to cervical cancer.

Increase in awareness about cancer diagnosis in the early stages and rise in demand for diagnostic & advanced screening techniques drive the global market. Moreover, high adoption rate of preventive diagnostic techniques among the population, technological advancements, and patient safety are expected to propel the cervical cancer diagnostic tests market in Asia Pacific, Latin America, and Middle East & Africa during the forecast period.

Pap Smear Test Segment to Dominate Global Cervical Cancer Diagnostic Tests Market

In terms of diagnostic test, the global cervical cancer diagnostic tests market has been classified into pap smear test, HPV test, colposcopy, biopsy and endocervical curettage, and other diagnostic tests. The pap smear test segment accounted for the largest market share in 2021, and the trend is likely to continue during the forecast period. This can be attributed to increase in the number of patients with high-risk HPV infection & cervical cancer across the globe and surge in incidence of teenage sex, along with low pricing of the test.

Patient Preference for Hospitals for Tests and Treatments to Drive Global Market

Based on end-user, the global cervical cancer diagnostic tests market has been divided into hospitals, specialty clinics, and others. The hospitals segment held key share of the global cervical cancer diagnostic tests market in 2021. The growth of the segment can be ascribed to the availability of multiple service options & devices and tie-ups with healthcare companies in order to enhance medical products and service offerings. Moreover, hospitals are the preferred choice of patients due to the availability of advanced equipment and better health care services.

The specialty clinics segment is projected to grow at a high CAGR, especially in developed countries, due to rise in cervical cancer cases and improvements in health care infrastructure & support.

Regional Outlook of Global Cervical Cancer Diagnostic Tests Market

In terms of region, the global cervical cancer diagnostic tests market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

North America held the largest share of the global cervical cancer diagnostic tests market in 2021, followed by Europe. North America dominated the market due to the presence of a large number of diagnostic kits and device providers, which helped cervical cancer patients in the region with easy access to screening solutions, rapid technological advancements, and assisted the baby boomer population that can afford high cost of diagnostic procedures. The high prevalence and incidence rate of cervical cancer among the population and increase in government initiatives on cancer awareness are likely to fuel the growth of the market in the next few years.

Some of the prominent players in the Cervical Cancer Diagnostic Tests Market include:

F. Hoffmann-La Roche Ltd., Abbott, Quest Diagnostics Incorporated, QIAGEN, Hologic, Inc., DYSIS Medical, Inc., Femasys, Inc., Guided Therapeutics, Inc., Cooper Companies, Inc., and BD.

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Cervical Cancer Diagnostic Tests market

• Diagnostic Test
• Pap Smear Test
• HPV Test
• Colposcopy
• Biopsy & Endocervical Curettage
• Other Diagnostic Tests
• End-user
• Hospitals
• Orthopedic Clinics
• Others

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa (MEA)

Key Benefits for Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global Cervical Cancer Diagnostic Tests industry analysis from 2022 to 2030 to identify the prevailing Cervical Cancer Diagnostic Tests industry opportunity.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the global Cervical Cancer Diagnostic Tests industry segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global Cervical Cancer Diagnostic Tests industry trends, key players, market segments, application areas, and market growth strategies.